Insmed Gains MHRA Authorisation for BRINSUPRI as Multi-Market Supply Demands Accelerate in 2026

With MHRA marketing authorisation secured for BRINSUPRI (brensocatib 25 mg tablets) in February 2026 and a Japanese regulatory decision anticipated before year-end, Insmed's manufacturing and supply chain functions face the immediate challenge of scaling GMP-compliant production across multiple concurrent market entries for a specialty respiratory asset.

BRINSUPRI revenues reached $207.9 million in Q1 2026, a 44% sequential increase over Q4 2025, driven predominantly by U.S. market uptake. ARIKAYCE (amikacin liposome inhalation suspension) contributed $98.1 million, up 6% year-over-year on international volume. Combined, total company revenues for the quarter were $306.0 million. Insmed reiterates full-year 2026 guidance of at least $1 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE, figures that set a measurable production throughput target for plant heads managing batch scheduling and capacity allocation.

The MHRA authorisation covers non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older presenting with two or more exacerbations in the preceding 12 months. For QA directors, the UK approval introduces a parallel pharmacovigilance and labelling compliance obligation alongside the existing 21 CFR Part 211 framework governing U.S. supply. Insmed has noted it continues to evaluate evolving U.S. trade and policy conditions that may affect the timing of additional international commercial launches, a variable that complicates forward demand planning.

On the ARIKAYCE side, positive topline results from the Phase 3b ENCORE study met its primary and all multiplicity-controlled secondary culture conversion endpoints in MAC lung disease. Insmed plans to submit a supplemental new drug application (sNDA) to the FDA in the second half of 2026 and to engage the PMDA in Japan during the same window for potential label expansion. A broader MAC indication would materially widen the eligible patient population, with direct consequences for batch sizing and liposome inhalation suspension manufacturing capacity.

The pipeline adds further process development pressure: the Phase 3 PALM-PAH study of treprostinil palmitil inhalation powder (TPIP) was initiated in April 2026, following FDA orphan drug designation granted in January. PALM-ILD, a parallel Phase 3 study in pulmonary hypertension associated with interstitial lung disease, continues enrolment. Two concurrent Phase 3 inhalation powder programmes running alongside a commercial-stage liposome suspension product represent a non-trivial process validation and technology transfer load under ICH Q10 pharmaceutical quality system expectations.

The sNDA submission window in H2 2026, combined with the anticipated Japan brensocatib decision, will serve as the near-term checkpoint for whether Insmed's supply network can absorb simultaneous regulatory interactions across three major markets without disruption to existing commercial commitments.

Source: Insmed Incorporated via PR Newswire, 7 May 2026.